Related Experiment Video
Updated: Aug 7, 2026
04:50
Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain
Published on: May 16, 2025
Meloxicam in rheumatoid arthritis
Mansoor Ahmed1, Dinesh Khanna, Daniel E Furst
1David Geffen School of Medicine, Los Angeles, CA, USA.
Expert Opinion on Drug Metabolism & Toxicology
|July 26, 2006
Summary
Meloxicam, a preferential COX-2 inhibitor, offers effective pain and inflammation relief for rheumatoid arthritis (RA) with fewer gastrointestinal side effects compared to traditional NSAIDs.
Area of Science:
- Rheumatology
- Pharmacology
Background:
- Rheumatoid arthritis (RA) is a chronic inflammatory disease requiring comprehensive management.
- Nonsteroidal anti-inflammatory drugs (NSAIDs) are used for symptomatic relief but carry risks of serious gastrointestinal (GI) adverse events.
- Meloxicam, a COX-2 preferential NSAID, is approved for RA and osteoarthritis treatment.
Purpose of the Study:
- To evaluate the efficacy and safety of meloxicam in managing rheumatoid arthritis.
- To compare the GI toxicity profile of meloxicam with non-selective NSAIDs.
Main Methods:
- Clinical trials were conducted to assess meloxicam's anti-inflammatory and analgesic properties.
- Comparative analysis of adverse effects, particularly GI toxicity, was performed against other NSAIDs like diclofenac, piroxicam, and naproxen.
Main Results:
- Meloxicam demonstrated comparable anti-inflammatory and analgesic efficacy to diclofenac, piroxicam, and naproxen at daily doses of 7.5-15 mg.
- Meloxicam was associated with a lower incidence of gastrointestinal adverse effects compared to non-selective NSAIDs.
Conclusions:
- Meloxicam provides effective symptom management for rheumatoid arthritis.
- Its COX-2 preferential activity translates to an improved gastrointestinal safety profile, making it a valuable therapeutic option for RA patients.
Related Concept Videos
01:21Rheumatic Heart Disease III: Medical Management
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...